Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. The company is headquartered in New York City, New York and currently employs 683 full-time employees. The company went IPO on 2015-11-19. The firm is engaged in developing and delivering therapies for central nervous system (CNS), conditions that have limited treatment options. The firm's two commercial products and development programs are Auvelity and Sunosi. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. AXS-05 is an oral, investigational NMDA receptor antagonist with multimodal activity under development for the treatment of Alzheimer's disease agitation (AD agitation) and smoking cessation. AXS-07 is an oral, rapidly absorbed, multi-mechanistic, investigational medicine under development for the acute treatment of migraine.
Follow-Up Questions
Who is the CEO of Axsome Therapeutics Inc?
Dr. Herriot Tabuteau is the Chairman of the Board of Axsome Therapeutics Inc, joining the firm since 2012.
What is the price performance of AXSM stock?
The current price of AXSM is $115.96, it has increased 0% in the last trading day.
What are the primary business themes or industries for Axsome Therapeutics Inc?
Axsome Therapeutics Inc belongs to Pharmaceuticals industry and the sector is Health Care
What is Axsome Therapeutics Inc market cap?
Axsome Therapeutics Inc's current market cap is $5.7B
Is Axsome Therapeutics Inc a buy, sell, or hold?
According to wall street analysts, 20 analysts have made analyst ratings for Axsome Therapeutics Inc, including 9 strong buy, 15 buy, 1 hold, 0 sell, and 9 strong sell
